T Cell Activation Bioassay (NFAT) Technical Manual
Instructions for Use of Product(s)
J1621, J1625, J1622, J1626, J1623, J1627
Literature # TM490
The T Cell Activation Bioassay (NFAT) is a bioluminescent cell-based assay that overcomes the limitations of existing assays and can be used for the discovery and development of novel biologic and cell therapies aimed at inducing, strengthening and/or engineering T cell responses. The assay consists of a genetically engineered Jurkat T cell line that expresses a luciferase reporter driven by an NFAT-response element (NFAT-RE). The TCR/CD3 Effector Cells (NFAT) are provided in Cell Propagation Model (CPM) format, which includes cryopreserved cells that can be thawed, propagated and banked for long-term use.
The TCR/CD3 Effector Cells express endogenous TCR, CD3 and CD28 receptors. When the TCR/CD3 Effector Cells (NFAT) are engaged with an appropriate TCR/CD3 ligand or anti-TCR/CD3 antibody, the TCR transduces intracellular signals resulting in NFAT-RE-mediated luminescence. The bioluminescent signal is detected and quantified using Bio-Glo™ Luciferase Assay System and a standard luminometer, such as the GloMax® Discover System.
This Technical Manual is relevant for Cat.# J1621 and J1625; J1622 and J1626 (Korea); J1623 and J1627 (Taiwan).
Summary of Changes
The following changes were made to the 1/24 revision of this document:
1. Updated patent statements.
2. Changed font and cover image.
3. Made minor text edits.
Revised 1/24